A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Volixibat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Shire
- 30 Apr 2017 Planned End Date changed from 1 Jun 2019 to 1 Jul 2020.
- 30 Apr 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Jul 2020.
- 29 Jul 2016 Status changed from not yet recruiting to recruiting.